Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 528
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Powles, T. Articles by Kanis, J. Search for Related Content PubMed Articles by Powles, T. Articles by Kanis, J.

Abstract

Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial

Parkside Oncology Clinic, Wimbleton, United Kingdom; University of Sheffield, Metabolic Bone Centre, Sheffield, United Kingdom; Schering OY, Helsinki, Finland

528

Background: The bisphosphonate clodronate (Bonefos) may reduce the incidence of bone metastases by inhibiting tumor-induced osteoclastic resorption of bone. Methods: This randomized, double-blind, placebo-controlled, multicenter trial evaluated the efficacy and safety of oral clodronate in 1,069 patients with primary operable stage I-III breast cancer from 1989–2000. Patients received oral clodronate (1600 mg/day) or placebo for 2 years, starting within 6 months of primary treatment (surgery, radiotherapy, and tamoxifen). Ad hoc analyses from this study have been published previously (Powles et al. JCO 2002), and the unpublished protocol-specified results and ad hoc analysis of stage II/III patients are reported here. The protocol-specified primary endpoint was time to first bone metastasis during the 5-year study period. The secondary endpoint was overall survival. These endpoints were analyzed by unstratified Log-rank test and hazard ratio (HR) with 95% CI. Results: Patient demographics were similar between treatment groups. Oral clodronate significantly reduced the risk of bone metastases by 45% in all patients during the medication period (2 years: HR = 0.546, P = 0.031), and by 31% during the study period (5 years: HR = 0.692, P = 0.043) compared to placebo. Similarly, clodronate significantly reduced the risk of bone metastases in patients with stage II/III disease during the medication (2 years: 50%, HR = 0.496, P = 0.020) and study (5 years: 41%, HR = 0.592, P = 0.009) periods. Oral clodronate vs. placebo significantly improved overall survival (23% reduction in risk of death: HR = 0.768, P = 0.048) and survival for stage II/III patients (26% reduction in risk of death: HR = 0.743, P = 0.041). Oral clodronate was well tolerated, with mild-to-moderate diarrhea being the most frequently reported adverse event. Conclusion: In patients with primary operable breast cancer, oral clodronate significantly reduced the risk of bone metastases and significantly improved survival rates during the medication and 5-year study periods compared to placebo. Similar results were seen in stage II/III patients.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering OY Schering AG Schering AG; Schering Oy Leiras Oy

Abstract presentation from the 2004 ASCO Annual Meeting